The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABOS | -21.56% | N/A | N/A | -90% |
| S&P | +16.23% | +94.45% | +14.22% | +56% |
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | -4.4% |
| Market Cap | $70.27M | -51.7% |
| Market Cap / Employee | $1.15M | 0.0% |
| Employees | 61 | 17.3% |
| Net Income | -$40.95M | -99.4% |
| EBITDA | -$41.70M | -71.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $36.81M | -45.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $29.96M | 1.2% |
| Short Term Debt | $0.14M | 13.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.32% | -31.5% |
| Return On Invested Capital | -30.53% | 16.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31.84M | -92.4% |
| Operating Free Cash Flow | -$31.83M | -92.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.61 | 0.48 | 0.36 | 0.45 | -18.58% |
| Price to Tangible Book Value | 0.61 | 0.48 | 0.36 | 0.45 | -18.58% |
| Enterprise Value to EBITDA | 0.66 | 0.97 | 1.74 | 1.03 | -70.60% |
| Return on Equity | -32.8% | -45.6% | -55.7% | -75.7% | 140.92% |
| Total Debt | $29.99M | $29.70M | $29.78M | $30.10M | 1.27% |
ABOS earnings call for the period ending June 30, 2022.
ABOS earnings call for the period ending March 31, 2022.
ABOS earnings call for the period ending December 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
